Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd (NATHBIOGEN) last reported results for the quarter ended Jun 2026, with sales of ₹328 crore and net profit of ₹32 crore. The stock last traded at ₹139, a market capitalisation of ₹264 crore, on a P/E of 7.79. Over the past 52 weeks the stock has ranged between ₹126 and ₹207. Figures are as of 6 Oct 2026 and are not real time.
Nath Bio-Genes (India) Ltd share price and key metrics
- Current price
- ₹139
- Market cap
- ₹264 cr
- Stock P/E
- 7.79
- Book value
- ₹358
- ROE
- 5.33%
- ROCE
- 7.16%
- Dividend yield
- 1.43%
- 52w high / low
- 207/126
Metrics as of 6 Oct 2026. Not real time.
Track Nath Bio-Genes (India) Ltd
Cruxal reads every Nath Bio-Genes (India) Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Nath Bio-Genes (India) Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 15%
- TTM
- 21%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 0%
- TTM
- 9%
- 10 Years
- 2%
- 5 Years
- -16%
- 3 Years
- -13%
- 1 Year
- -22%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 6%
- Last Year
- 5%
Nath Bio-Genes (India) Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹328 cr, up 15.5% from ₹284 cr a year earlier. Net profit was ₹32 cr, up 14.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 37 | 52 | 284 | 44 | 66 | 52 | 328 |
| Expenses | 27 | 29 | 52 | 254 | 38 | 62 | 47 | 293 |
| Operating profit | 5 | 8 | 0 | 29 | 6 | 4 | 4 | 35 |
| OPM % | 15% | 22% | 0.8% | 10% | 14% | 5% | 9% | 11% |
| Other income | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 4 | 2 | 29 | 5 | 2 | 2 | 33 |
| Tax % | -3% | 30% | 30% | 2% | 12% | 35% | 100% | 2% |
| Net profit | 1 | 3 | 1 | 28 | 5 | 2 | -0 | 32 |
| EPS (₹) | 0.58 | 1.39 | 0.78 | 14.88 | 2.54 | 0.84 | -0.01 | 16.98 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Nath Bio-Genes (India) Ltd annual results
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 97 | 109 | 230 | 234 | 248 | 268 | 358 | 490 |
| Operating profit | 15 | 20 | 37 | 49 | 50 | 51 | 53 | 49 |
| OPM % | 15% | 18% | 16% | 21% | 20% | 19% | 15% | 10% |
| Net profit | 9 | 12 | -67 | 35 | 40 | 39 | 42 | 39 |
| EPS (₹) | 5.75 | 7.34 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 | 20.35 |
TTM is the trailing twelve months to the most recent quarter.
Nath Bio-Genes (India) Ltd balance sheet
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 30 | 41 | 523 | 554 | 591 | 625 | 661 |
| Borrowings | 11 | 19 | 93 | 105 | 110 | 123 | 138 |
| Other liabilities | 63 | 82 | 105 | 114 | 160 | 259 | 278 |
| Total liabilities | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
| Fixed assets | 21 | 38 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 5 | 5 | 6 | 6 | 6 |
| Other assets | 99 | 121 | 490 | 543 | 625 | 770 | 842 |
| Total assets | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
As reported by the company. Total assets equal total liabilities by construction.
Nath Bio-Genes (India) Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 17 | 38 | 75 | 18 | -13 |
| Cash from investing | -20 | -3 | -27 | -4 | 3 |
| Cash from financing | -22 | -2 | -8 | -2 | -4 |
| Net cash flow | -25 | 34 | 39 | 11 | -13 |
| Free cash flow | 16 | 36 | 48 | 10 | -16 |
| CFO / operating profit | 54% | 80% | 150% | 37% | -22% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Nath Bio-Genes (India) Ltd operating ratios
| Per year | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 24% | — | 7% | 7% | 7% | 7% |
| Debtor days | 47 | 70 | 136 | 152 | 139 | 121 | 87 |
| Inventory days | 587 | 667 | — | 4,388 | — | — | — |
| Days payable | 146 | 239 | — | 586 | — | — | — |
| Cash conversion cycle | 487 | 499 | 136 | 3,954 | 139 | 121 | 87 |
| Working capital days | 79 | 64 | 427 | 415 | 342 | 321 | 314 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Nath Bio-Genes (India) Ltd shareholding pattern
Promoters held 45.59% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.26% and DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% |
| FIIs | 0.18% | 0.19% | 0.21% | 0.41% | 0.32% | 0.31% | 0.22% | 0.26% |
| DIIs | 4.37% | 4.37% | 3.94% | 2.25% | 0.76% | 0.01% | 0.01% | 0.01% |
| Public | 49.83% | 49.83% | 50.24% | 51.73% | 53.31% | 54.08% | 54.17% | 54.13% |
| No. of shareholders | 35,423 | 35,056 | 34,911 | 34,207 | 34,122 | 33,550 | 33,031 | 32,564 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Nath Bio-Genes (India) Ltd corporate filings
- Closure of Trading windowInsider Trading / SASTlow impact
- Nath Bio-Genes (India) Limited concludes 33rd AGM; shareholders approve final dividend of INR 2 per shareAGM/EGMlow impact
Cruxal's analysis: Nath Bio-Genes (India) Limited has successfully concluded its 33rd Annual General…
Read the full analysis - Nath Bio-Genes (India) Limited schedules 33rd AGM for September 24, 2026, and sets record date for dividend eligibilityCorp Actionlow impact
Cruxal's analysis: Nath Bio-Genes (India) Limited has announced that its 33rd Annual General Meeting will be…
Read the full analysis - Nath Bio-Genes (India) Limited schedules 33rd Annual General Meeting for 24th September 2026Corp. Actionlow impact
Cruxal's analysis: Nath Bio-Genes (India) Limited has formally announced that its 33rd Annual General…
Read the full analysis - Nath Bio-Genes (India) Ltd announces Annual General Meeting and releases Annual ReportOtherslow impact
Cruxal's analysis: Nath Bio-Genes (India) Ltd has filed its notice for the Annual General Meeting and the…
Read the full analysis - Nath Bio-Genes (India) Limited Announces FY26 Financial Results, Dividend Declaration, and Board Re-appointmentsAGM/EGMhigh impact
Cruxal's analysis: Nath Bio-Genes (India) Limited reported standalone revenue from operations of 431.60…
Read the full analysis - Nath Bio-Genes (India) Ltd announces initiation of forensic auditCompany Updatemedium impact
Cruxal's analysis: The company has formally intimated the initiation of a forensic audit under Regulation 30…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.